A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules

NCT00001037 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

22

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: gp160 Vaccine (Immuno-AG)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)